Date published: 2026-1-9

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olfr794 Activators

Olfr794 is a part of the olfactory receptor family, a diverse group of G protein-coupled receptors (GPCRs) critical for detecting a wide array of odorant molecules. These receptors, including Olfr794, are responsible for the initiation of the olfactory signal transduction pathway. Activation of these receptors typically involves the binding of specific odorant molecules, which leads to conformational changes in the receptor structure. These changes facilitate the coupling of the receptor with G proteins, triggering a sequence of intracellular signaling events that ultimately result in the perception of smell. The specific ligands and broader physiological roles of Olfr794 are not fully understood, which is a common challenge in the study of olfactory receptors due to their highly specific and varied ligand affinity. The activation of Olfr794, as with other GPCRs, is subject to modulation by various cellular factors and signaling molecules. One key regulatory mechanism in GPCR function is the cyclic adenosine monophosphate (cAMP) signaling pathway. cAMP serves as a secondary messenger within cells and plays a crucial role in regulating numerous cellular processes, including GPCR signaling. The generation of cAMP is controlled by adenylate cyclase, which converts ATP into cAMP in response to external stimuli. The accumulation of cAMP can activate protein kinase A (PKA), resulting in the phosphorylation of different target proteins, including GPCRs themselves. This phosphorylation can modulate the receptor's responsiveness to ligands, altering its activation dynamics. Furthermore, cAMP can influence other signaling pathways that intersect with GPCR signaling, thereby indirectly affecting the activity of receptors such as Olfr794.

Phosphodiesterases (PDEs), which are responsible for the breakdown of cAMP, are critical in maintaining its intracellular levels. Inhibitors of PDEs can lead to an increase in cAMP concentration within the cell, indirectly influencing GPCR signaling. This increase in cAMP, caused by PDE inhibition, can indirectly modulate the activity of Olfr794 through various mechanisms, including changes in receptor phosphorylation, ligand-receptor interactions, and receptor-G protein coupling. Additionally, compounds that directly increase cAMP levels, such as activators of adenylate cyclase or β-adrenergic receptor agonists, can also indirectly affect the activity of Olfr794. These diverse interactions demonstrate the complexity of GPCR regulation and underline the potential of various chemical compounds to modulate the activity of receptors like Olfr794 indirectly. In summary, understanding the activation mechanisms of Olfr794 is crucial for gaining insights into the olfactory system and the broader role of GPCRs in physiological processes. The intricate interplay between different cellular components and signaling molecules, as well as the potential for modulation by external compounds, highlights the complexity and significance of studying these receptors.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Isoproterenol Hydrochloride

51-30-9sc-202188
sc-202188A
100 mg
500 mg
$28.00
$38.00
5
(0)

Isoproterenol, a synthetic catecholamine and β-adrenergic agonist, increases intracellular cAMP through adenylate cyclase activation. Increased cAMP could indirectly modulate Olfr794 signaling pathways, enhancing receptor activation and signal transduction.

IBMX

28822-58-4sc-201188
sc-201188B
sc-201188A
200 mg
500 mg
1 g
$260.00
$350.00
$500.00
34
(1)

3-Isobutyl-1-methylxanthine (IBMX), a non-selective phosphodiesterase inhibitor, raises cAMP and cGMP levels, potentially influencing Olfr794 indirectly by modulating GPCR signaling pathways, altering receptor dynamics, and enhancing signaling efficacy.

(−)-Epinephrine

51-43-4sc-205674
sc-205674A
sc-205674B
sc-205674C
sc-205674D
1 g
5 g
10 g
100 g
1 kg
$41.00
$104.00
$201.00
$1774.00
$16500.00
(1)

Epinephrine, an endogenous catecholamine, stimulates α and β-adrenergic receptors to increase cAMP via adenylate cyclase. This surge in cAMP could indirectly affect Olfr794 activation, potentially enhancing its activity through downstream signaling cascades.

Rolipram

61413-54-5sc-3563
sc-3563A
5 mg
50 mg
$77.00
$216.00
18
(1)

Rolipram inhibits phosphodiesterase 4 (PDE4), leading to increased cAMP levels. Elevated cAMP may enhance Olfr794 activity by modulating intersecting GPCR signaling pathways, altering receptor dynamics, and impacting downstream signaling.

Cilostamide (OPC 3689)

68550-75-4sc-201180
sc-201180A
5 mg
25 mg
$92.00
$357.00
16
(1)

Cilostamide, a selective PDE3 inhibitor, raises intracellular cAMP, potentially influencing Olfr794 activation by affecting GPCR-mediated signaling pathways, possibly through changes in receptor trafficking or signaling efficiency.

Salbutamol

18559-94-9sc-253527
sc-253527A
25 mg
50 mg
$94.00
$141.00
(1)

Salbutamol, a β2-adrenergic agonist, increases cAMP levels via adenylate cyclase activation. This rise might boost Olfr794 activity by impacting GPCR-linked pathways, potentially enhancing receptor activation and signal transduction.

Theophylline

58-55-9sc-202835
sc-202835A
sc-202835B
5 g
25 g
100 g
$20.00
$32.00
$85.00
6
(0)

Theophylline, a non-selective phosphodiesterase inhibitor, increases cAMP and cGMP levels. Elevated cAMP might stimulate Olfr794 by influencing associated GPCR signaling pathways, potentially affecting receptor conformation and signaling.

Dobutamine

34368-04-2sc-507555
100 mg
$295.00
(0)

Dobutamine, a synthetic catecholamine, targets β1-adrenergic receptors, increasing cAMP. This elevation could modulate Olfr794 activity by affecting GPCR-mediated signaling pathways, leading to changes in receptor activation dynamics.

Milrinone

78415-72-2sc-201193
sc-201193A
10 mg
50 mg
$165.00
$697.00
7
(0)

Milrinone, a selective PDE3 inhibitor, enhances cAMP levels, potentially influencing Olfr794 activation by affecting related GPCR signaling pathways, modifying receptor responsiveness and signaling efficacy.